Shandong Xinhua Pharmaceutical Secures Regulatory Approval for Vonoprazan Fumarate API
I'm PortAI, I can summarize articles.
Shandong Xinhua Pharmaceutical Company Limited has received regulatory approval from the National Medical Products Administration for its Vonoprazan Fumarate API. This approval is expected to expand the company's product line and enhance competitiveness. The announcement notes that the pharmaceutical sales business is subject to industry policy changes and market factors. The original content was published by Shandong Xinhua Pharmaceutical on November 17, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments